

48  
DT  
2-16-01

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


RECEIVED

In re Application of:

KJETIL TASKÉN et al

Appln. No.: 09/428,458

Filed: October 28, 1999



FEB 14 2001

TECH CENTER 1600/2000

Group Art Unit: 1623

Examiner: Unknown

For: USE OF IMMUNOMODULATING AGENTS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.97 and 1.98

Assistant Commissioner  
for Patents  
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicants hereby notify the U.S. Patent and Trademark Office of the documents which are listed on the attached Form PTO-1449 which the Examiner may deem relevant to patentability of the claims of the above-identified application.

A copy of the listed documents are submitted herewith.

The present Supplemental Information Disclosure Statement is being filed before after months from the application's filing date, but before the mailing date of the first Office Action on the merits, therefore no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed document is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicants do not waive any right to take any action that would be appropriate to

**SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT  
U.S. Appln. No. 09/428,458**

antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

Respectfully submitted,

  
Gordon Kit  
Registration No. 30,764

**SUGHRUE, MION, ZINN,  
MACPEAK & SEAS, PLLC**  
2100 Pennsylvania Avenue, N.W.  
Washington, D.C. 20037-3213  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

Date: February 13, 2001